【阿斯利康依普隆特生钠注射液在华上市】从阿斯利康获悉,7月8日,阿斯利康与Ionis公司联合开发的依普隆特生钠注射液在中国正式上市。该药于2025年12月在国内获批,用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.